Form 4: Sangamo Exec's RSU Vesting and Tax Withholding

SVP-Chief Development Officer Nathalie Dubois-Stringfellow reported a routine disposition of 2,544 Sangamo Therapeutics shares for tax withholding following an RSU vesting event.

Summary

• Nathalie Dubois-Stringfellow, SVP-Chief Development Officer of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on November 24, 2025.
• 2,544 shares of Sangamo Therapeutics, Inc. common stock were disposed of at a price of $0.4166 per share.
• This disposition was solely for mandatory tax withholding purposes related to a restricted stock unit (RSU) grant that vested on November 24, 2025, and was not a discretionary trade.
• Following this transaction, Dubois-Stringfellow beneficially owns 719,804 shares of common stock.
• The beneficial ownership includes 2,466 shares resulting from the November 24, 2025 vesting installment of a February 24, 2023 RSU grant.
• Future vesting includes 5,010 shares from the February 24, 2023 RSU grant on February 24, 2026.
• 89,063 shares from a January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026.
• 120,000 shares from a February 25, 2025 RSU grant will vest as to one-fourth on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.
• All RSU vesting is contingent on continuous service and subject to acceleration under the Issuer's Amended and Restated 2018 Equity Incentive Plan.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding related to RSU vesting. This is a neutral event, neither significantly positive nor negative for the company's outlook.

Positives

• The executive continues to hold a substantial number of shares (719,804), indicating continued alignment with shareholder interests.
• The vesting of RSUs represents a successful milestone for the executive's compensation plan, reflecting the achievement of performance or tenure conditions.

Negatives

• A disposition of shares, even for tax purposes, results in a slight reduction of the executive's direct share ownership.

Future Outlook

The filing details future vesting schedules for the reporting person's restricted stock units, with significant portions expected to vest on February 24, 2026, January 22, 2026, and in quarterly installments starting February 25, 2026, all subject to continuous service.

Industry Context

This is a routine insider transaction filing (Form 4) related to executive compensation. It does not provide broader industry context or trends, but such filings are common across all publicly traded companies as part of executive equity compensation plans.

Related Party Transactions

• The disposition of shares to the issuer for mandatory tax withholding purposes is a transaction between the reporting person and the company, as per the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan.

Stakeholder Impact

• Shareholders: Minimal direct impact. The transaction is a routine administrative event related to executive compensation and does not reflect a change in company fundamentals or strategy. The executive's continued significant share ownership aligns interests.
• Employees: The RSU vesting and tax withholding process is a standard component of executive compensation, reflecting the company's established incentive plans.

Next Steps

• Vesting of 5,010 shares from the February 24, 2023 RSU grant on February 24, 2026.
• Continued vesting of 89,063 shares from the January 22, 2024 RSU grant in successive equal quarterly installments through January 22, 2026.
• Vesting of one-fourth of the 120,000 shares from the February 25, 2025 RSU grant on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Executive Compensation, Nathalie Dubois-Stringfellow, Beneficial Ownership